MARKET

DNLI

DNLI

Denali
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.20
-0.24
-1.38%
After Hours: 17.20 0 0.00% 17:01 04/03 EDT
OPEN
17.54
PREV CLOSE
17.44
HIGH
17.69
LOW
16.54
VOLUME
284.95K
TURNOVER
--
52 WEEK HIGH
30.41
52 WEEK LOW
12.39
MARKET CAP
1.81B
P/E (TTM)
-8.3241
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DNLI stock price target is 28.36 with a high estimate of 36.00 and a low estimate of 18.00.

EPS

DNLI News

More
  • The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
  • Benzinga · 11h ago
  • Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic
  • GlobeNewswire · 1d ago
  • Still more COVID-19 actions - healthcare
  • Seeking Alpha - Article · 1d ago
  • Goldman sees 143% upside in Amarin in premarket analyst action
  • Seeking Alpha - Article · 03/13 11:26

Industry

Biotechnology & Medical Research
-0.74%
Pharmaceuticals & Medical Research
-0.56%

Hot Stocks

Symbol
Price
%Change

About DNLI

Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.
More

Webull offers kinds of Denali Therapeutics Inc stock information, including NASDAQ:DNLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNLI stock news, and many more online research tools to help you make informed decisions.